Table 3.

p scores for OS, in the entire cohort and in respective subgroups, derived from individual patient data meta-analysis

	Entire cohort	HBV	HCV	Nonviral	BCLC B	BCLC C	AFP ≥400	AFP <400	MVI	EHS	MVI/EHS	No MVI/EHS
Anti-PD-(L)1/VEGF Ab	0.993	0.898	0.984	0.374	0.904	0.962	0.645	0.992	0.960	0.950	0.956	0.966
Ate-Cab	0.519	0.918	0.300	0.198							0.676	0.171
T300+D	0.851	0.824	0.330	0.947	0.499	0.649	0.716	0.601	0.777	0.795	0.774	0.766
Durvalumab	0.710
Nivolumab	0.727	0.661	0.780	0.551	0.235	0.595	0.637	0.241			0.756	0.323
Lenvatinib	0.552	0.599	0.525		0.470	0.251					0.526	0.404
Linifanib	0.321	0.387									0.144	0.699
Brivanib	0.235	0.297	0.739						0.393		0.353	0.696
Sunitinib	0.079	0.183	0.033						0.157
Sor-Erl	0.603	0.372	0.417						0.700	0.408
Sorafenib	0.390	0.326	0.391	0.431	0.392	0.043	0.003	0.165	0.469	0.312	0.296	0.450
Placebo	0.021	0.037							0.045	0.035	0.018	0.026

p scores are a measure of treatment efficacy with higher scores corresponding to higher efficacy. Blanks indicate that HRs for the subgroup were not reported for studies involving that treatment. AFP, alpha-fetoprotein; Anti-PD-(L)1/VEGF Ab, anti-programmed death-1/programmed death-ligand-1 pathway plus vascular endothelial growth receptor monoclonal antibody; Ate-Cab, atezolizumab-cabozantinib; BCLC, Barcelona Clinic Liver Cancer; EHS, extrahepatic spread; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, macrovascular invasion; T300+D, tremelimumab-durvalumab; Sor-Erl, sorafenib-erlotinib.